Drugs / XSTEM-OA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05344157 | Jun 2022 → Jun 2025 | osteoarthritis, knee | Xindu Pty Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XSTEM-OA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05344157 ↗ |
| Modality | Cell therapy | “mesenchymal stem cell (MSC) product” NCT05344157 ↗ |
| Route | Other | “administered as a single intra-articular injection” NCT05344157 ↗ |